Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
ATLANTA, June 28, 2017 -- Using microneedle patch technology under development at Micron Biomedical, Inc. (Micron), a Phase 1 clinical trial showed that vaccination by microneedle patch was as safe and at least as immunogenic as vaccination with standard needle and syringe. The trial was carried out by the Georgia Institute of Technology (Georgia Tech) and the Emory University Hope Clinic. The results were published in the prestigious medical journal The Lancet (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30575-5/fulltext?elsca1=tlpr).
“We are very pleased with these results,” says Devin McAllister, PhD, Micron’s Vice President, R&D, and co-founder, “as they show the great potential of the painless, applicator-free microneedle patch technology platform that Micron is building upon to improve delivery of drugs and vaccines.”
The first-in-humans, Phase 1 clinical trial enrolled 100 subjects and investigated the safety, immunogenicity, and acceptability of a seasonal flu vaccine delivered either by microneedle patch or by standard hypodermic needle and syringe. The study also compared the ability of study participants to self-administer the microneedle patches.
The results showed that vaccination by microneedle patch was safe, well tolerated by study participants, and generated an immune response that was at least as strong as with the standard intramuscular injection. Moreover, subjects overwhelmingly (>70%) preferred the microneedle patch over the needle and syringe as their future vaccination method. The study also showed that participants could self-administer the patch.
The microneedle patch technology used in the study was developed at Georgia Tech in the laboratory of Mark Prausnitz, PhD, Regents’ Professor of Chemical and Biomolecular Engineering and is now being licensed and developed for commercialization by Micron. Dr. Prausnitz co-founded Micron and serves as its Chief Scientific Officer. “The phase 1 clinical trial confirms that the microneedle patch technology is safe, immunogenic, easy to use, and preferred by people,” says Dr. Prausnitz, who adds that, “Micron is leveraging these excellent results to continue the pre-clinical and clinical development of its microneedle patch product portfolio.”
About Micron Biomedical
Micron is a biopharmaceutical company on a rapid path to commercialize its novel vaccine and drug delivery technology, based on dissolving microneedle patches, aimed at achieving better health outcomes through enhanced therapeutic effects, simplified logistics, and improved patient compliance.
Media Contact Information: Sebastien Henry, MS, MBA Vice President, Program Management Tel: 770-722-0306 [email protected] www.micronbiomedical.com
